IP Library Granted Patent US 10,793,824
Granted Patent B2
US 10,793,824 · App. 16/000,358 · Granted Oct 6, 2020

Salt formulations for the fermentation of marine microorganisms

Inventors: Kin Sing Lam (San Diego, CA); Ginger Tsueng (San Diego, CA)
Assignee: Celgene International II Sárl
C12N1/20C12P17/188C12N2500/05C12N2500/12C12N2500/14C12N2500/16C12N2500/20C12N2500/38Y10S435/822
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,793,824
App. No.
16/000,358
Granted
Oct 6, 2020
Kind
B2
Abstract

Growth medium are disclosed for use in fermenting a marine microorganism. The medium comprise Potassium, Calcium, Strontium, Borate and Fluoride at specific concentrations. Alternatively, the growth medium comprises cobalt at specified concentrations or comprises vitamin B 12 at specified concentrations. Methods of producing certain desired compound by fermentation of a marine microorganism are also disclosed.

Claims (29)

1. A salt formulation for use in fermenting a marine microorganism, the formulation comprising:

(a) NaCl in the salt formulation at a mass percent between 92% and 76%;

(c) KCl in the salt formulation at a mass percent between 5% and 1.50%;

(d) CaCl 2 ⋅H 2 O in the salt formulation at a mass percent between 3% and 1%;

(e) SrCl 2 in the salt formulation at a mass percent between 0.10% and 0.025%;

(f) H 3 BO 3 ⋅7H 2 O in the salt formulation at a mass percent between 0.20% and 0.04%; and

(g) NaF in the salt formulation at a mass percent between 0.05% and 0.005%.

2. The salt formulation of claim 1 , further comprising CaCO 3 at a mass percent between 5% and 1%.

3. The salt formulation of claim 1 , further comprising CoCl 2 ⋅6H 2 O.

4. The salt formulation of claim 1 , further comprising KBr at a mass percent between 3% and 0.10%.

5. The salt formulation of claim 1 , further comprising Fe 2 (SO 4 ) 3 .

6. A salt formulation for use in fermenting a marine microorganism, the formulation comprising:

(a) Na 2 SO 4 at a mass percent between 85% and 72%;

(c) KCl at a mass percent between 5% and 3%;

(d) CaCl 2 ⋅H 2 O at a mass percent between 3% and 1%;

(e) SrCl 2 at a mass percent between 0.15% and 0.05%;

(f) H 3 BO 3 ⋅7H 2 O at a mass percent between 0.30% and 0.10%; and

(g) NaF at a mass percent between 0.03% and 0.01%.

7. The salt formulation of claim 6 , further comprising CaCO 3 at a mass percent between 20% and 0.5%.

8. The salt formulation of claim 6 , further comprising CoCl 2 ⋅6H 2 O.

9. The salt formulation of claim 6 , further comprising KBr at a mass percent between 3% and 0.10%.

10. The salt formulation of claim 6 , further comprising Fe 2 (SO 4 ) 3 .

11. A salt formulation for use in fermenting a marine microorganism, the formulation comprising:

(a) KCl at a mass percent between 90% and 75%;

(b) MgSO 4 at a mass percent between 20% and 5%

(c) CaCl 2 at a mass percent between 5% and 3%;

(d) SrCl 2 at a mass percent between 0.3% and 0.03%;

(e) H 3 BO 3 at a mass percent between 0.4% and 0.04%; and

(f) NaF at a mass percent between 0.03% and 0.01%.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2019
From: LAM, KIN SING; TSUENG, GINGER
To: NEREUS PHARMACEUTICALS, INC.
Reel/Frame 048050/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2019
From: CELGENE RESEARCH AND DEVELOPMENT I ULC, FORMERLY KNOWN AS TRIPHASE RESEARCH AND DEVELOPMENT I CORP.
To: 1096271 B.C. UNLIMITED LIABILITY COMPANY
Reel/Frame 048050/0392 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2019
From: 1096271 B.C. UNLIMITED LIABILITY COMPANY
To: CELGENE TRI A HOLDINGS LTD.
Reel/Frame 048050/0618 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2019
From: CELGENE TRI A HOLDINGS LTD.
To: CELGENE INTERNATIONAL II SARL
Reel/Frame 048050/0671 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2019
From: NEREUS PHARMACEUTICALS, INC.
To: TRIPHASE RESEARCH AND DEVELOPMENT I CORP.
Reel/Frame 048086/0888 →
Continuity (7)
Division 14624183 · Feb 17, 2015
Division 11860491 · Sep 24, 2007
Provisional Application 60952349 · Jul 27, 2007
Provisional Application 60952368 · Jul 27, 2007
Provisional Application 60949147 · Jul 11, 2007
Provisional Application 60846774 · Sep 22, 2006
Related Publication 20180282686A1 · Oct 4, 2018